---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-154347"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2023-05-25T23:59:59+00:00"
generated_at: "2026-06-14T14:49:04.934253+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cullinan reports Phase 1 CLN-619 data: 1 CR, 2 PRs in solid tumors; expansion in endometrial/cervical cancers

## Summary
- CLN-619 monotherapy showed 1 complete response (parotid gland cancer) and 2 unconfirmed partial responses (endometrial cancer) in heavily pre-treated patients.
- 54% of patients had prior checkpoint inhibitor therapy; responses observed in patients who progressed on prior CPI.
- No dose-limiting toxicities across 0.1-10 mg/kg doses; infusion reactions Grade 1/2 only with pre-medication.
- Based on gynecologic activity, company will initiate monotherapy expansion cohorts in endometrial and cervical cancers.
- Phase 1 trial continues enrolling monotherapy and combination (with pembrolizumab) arms; future results to be shared.

## SEC filing metadata
- accession: 0001193125-23-154347
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2023-05-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312523154347/0001193125-23-154347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312523154347/d462773d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-154347
- JSON: https://secwatch.observer/filing/0001193125-23-154347.json
- Plain text: https://secwatch.observer/filing/0001193125-23-154347.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.